Author: Xiaoban Xin
Published: August 25, 2021
On August 3, 2021, the China National Intellectual Property Administration (CNIPA) released the Draft Revised Patent Examination Guidelines (“Draft Guidelines”) for comments. The revisions in the Draft Guidelines reflect the recently amended Chinese Patent Law that came into effect on June 1, 2021, and the Draft Revised Implementing Regulations (“Draft Regulations”) of the Chinese Patent Law. This article summarizes selected provisions in the Draft Guidelines that are relevant to pharmaceutical products.
Click here to view the entire article at Rothwell, Figg, Ernst & Manbeck P.C.